Alcon to acquire Ivantis for USD 475 Million
Alcon announced that it intends to buy glaucoma surgery device maker Ivantis for USD 475 million upfront.
Geneva, Switzerland-based Alcon aims to support its portfolio across cataract, refractive, retina and glaucoma offerings by taking over Ivantis and its novel Hydrus Microstent for minimally invasive glaucoma surgery (MIGS).
Ivantis designed the Hydrus Microstent to decrease intraocular pressure for open-angle glaucoma patients in connection with cataract surgery. A five-year study showed that 65% of Hydrus Microstent patients remained medication-free at five years post-implant with a more than 60% reducti...
